Zhejiang Hisun Pharmaceutical Past Earnings Performance
Past criteria checks 0/6
Zhejiang Hisun Pharmaceutical has been growing earnings at an average annual rate of 22.3%, while the Pharmaceuticals industry saw earnings growing at 9.4% annually. Revenues have been growing at an average rate of 1.7% per year.
Key information
22.3%
Earnings growth rate
20.5%
EPS growth rate
| Pharmaceuticals Industry Growth | 10.9% |
| Revenue growth rate | 1.7% |
| Return on equity | -1.1% |
| Net Margin | -0.8% |
| Last Earnings Update | 31 Mar 2024 |
Revenue & Expenses BreakdownBeta
How Zhejiang Hisun Pharmaceutical makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 10,036 | -77 | 3,189 | 384 |
| 31 Dec 23 | 10,373 | -93 | 3,277 | 392 |
| 30 Sep 23 | 11,994 | 615 | 3,436 | 454 |
| 30 Jun 23 | 12,360 | 589 | 3,509 | 458 |
| 31 Mar 23 | 12,123 | 586 | 3,427 | 442 |
| 31 Dec 22 | 12,037 | 489 | 3,422 | 429 |
| 30 Sep 22 | 11,773 | 319 | 3,329 | 395 |
| 30 Jun 22 | 11,869 | 526 | 3,402 | 394 |
| 31 Mar 22 | 12,046 | 496 | 3,443 | 379 |
| 31 Dec 21 | 12,136 | 487 | 3,466 | 373 |
| 30 Sep 21 | 12,308 | 574 | 3,540 | 403 |
| 30 Jun 21 | 12,040 | 457 | 3,499 | 380 |
| 31 Mar 21 | 11,923 | 614 | 3,366 | 403 |
| 31 Dec 20 | 11,354 | 417 | 3,355 | 401 |
| 30 Sep 20 | 10,914 | -819 | 3,489 | 726 |
| 30 Jun 20 | 10,724 | 281 | 3,626 | 892 |
| 31 Mar 20 | 10,774 | -10 | 3,903 | 890 |
| 31 Dec 19 | 11,072 | 93 | 3,923 | 904 |
| 30 Sep 19 | 10,694 | 755 | 3,880 | 780 |
| 30 Jun 19 | 10,522 | -455 | 3,630 | 640 |
| 31 Mar 19 | 10,163 | -472 | 3,418 | 641 |
| 31 Dec 18 | 10,187 | -492 | 3,264 | 640 |
| 30 Sep 18 | 10,200 | 16 | 2,976 | 468 |
| 30 Jun 18 | 10,398 | 15 | 2,548 | 633 |
| 31 Mar 18 | 10,655 | 18 | 2,359 | 526 |
| 31 Dec 17 | 10,572 | 14 | 2,230 | 439 |
| 30 Sep 17 | 10,574 | -120 | 2,155 | 271 |
| 30 Jun 17 | 10,509 | -101 | 2,424 | 0 |
| 31 Mar 17 | 10,090 | -94 | 2,351 | 0 |
| 31 Dec 16 | 9,733 | -94 | 2,302 | 0 |
| 30 Sep 16 | 9,396 | 40 | 2,257 | 0 |
| 30 Jun 16 | 8,986 | -3 | 2,232 | 0 |
| 31 Mar 16 | 8,793 | 15 | 2,183 | 0 |
| 31 Dec 15 | 8,767 | 14 | 2,168 | 0 |
| 30 Sep 15 | 9,382 | 85 | 2,303 | 0 |
| 30 Jun 15 | 9,835 | 175 | 2,352 | 0 |
| 31 Mar 15 | 10,145 | 237 | 2,470 | 0 |
| 31 Dec 14 | 10,097 | 308 | 2,475 | 0 |
| 30 Sep 14 | 9,645 | 314 | 2,323 | 0 |
| 30 Jun 14 | 9,104 | 311 | 2,248 | 0 |
| 31 Mar 14 | 8,895 | 303 | 2,218 | 0 |
| 31 Dec 13 | 8,604 | 302 | 2,201 | 0 |
| 30 Sep 13 | 7,785 | 268 | 1,972 | 0 |
| 30 Jun 13 | 7,178 | 291 | 1,628 | 0 |
Quality Earnings: 600267 is currently unprofitable.
Growing Profit Margin: 600267 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 600267 is unprofitable, but has reduced losses over the past 5 years at a rate of 22.3% per year.
Accelerating Growth: Unable to compare 600267's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 600267 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-1.5%).
Return on Equity
High ROE: 600267 has a negative Return on Equity (-1.11%), as it is currently unprofitable.